Abstract
Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVG) is associated with worse outcomes as compared with native coronary arteries. Previous studies comparing drug-eluting stents (DES) with bare metal stents (BMS) for PCI of SVG have yielded inconsistent results. Therefore, we aimed to perform a comprehensive meta-analysis of randomised trials comparing DES versus BMS for SVG PCI. Randomised trials that reported clinical outcomes and compared DES versus BMS for PCI of SVG were included. Summary estimates risk ratios (RRs) were constructed using a DerSimonian and Laird model. The primary outcome was major adverse cardiac events (MACE). Five trials with 1,535 patients were analysed. At a mean of 24.5 months, there was no difference in the risk of MACE (22.7% in the DES group versus 33.5% in the BMS group; RR 0.75, 95% CI: 0.49-1.16), all-cause mortality (9.5% versus 5.6%; RR 1.30, 95% CI: 0.77-2.18), cardiac mortality (5.5% versus 3.6%; RR 1.29, 95% CI: 0.53-3.15), myocardial infarction (7.1% versus 11.7%; RR 0.70, 95% CI: 0.40-1.22), stent thrombosis (2.5% versus 6.1%; RR 0.73, 95% CI: 0.26-2.03), and target vessel revascularisation (11.7% versus 24.4%; RR 0.66, 95% CI: 0.41-1.04) between DES and BMS. Data from randomised trials indicate that DES are safe for PCI for SVG disease. The risk of MACE, mortality, myocardial infarction, stent thrombosis or target vessel revascularisation was not statistically significantly different between the devices. Novel therapies are needed in the management of this subset of patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.